These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16358237)

  • 1. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
    Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
    J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CME. Fabry disease: rare but not to be missed].
    Steinack C; Gaspert A; Kovacs R; Nowak A
    Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
    [No Abstract]   [Full Text] [Related]  

  • 9. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agalsidase alfa: specific treatment for Fabry disease.
    Mehta A
    Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
    Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
    Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
    Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
    Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.
    Hauser AC; Lorenz M; Sunder-Plassmann G
    J Intern Med; 2004 Jun; 255(6):629-36. PubMed ID: 15147526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
    Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
    Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
    Ramaswami U
    Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
    Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
    Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.
    Whybra C; Kampmann C; Krummenauer F; Ries M; Mengel E; Miebach E; Baehner F; Kim K; Bajbouj M; Schwarting A; Gal A; Beck M
    Clin Genet; 2004 Apr; 65(4):299-307. PubMed ID: 15025723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fabry-Anderson disease: current state of knowledge].
    Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
    Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.